vs
Side-by-side financial comparison of 4D Molecular Therapeutics, Inc. (FDMT) and COMSCORE, INC. (SCOR). Click either name above to swap in a different company.
COMSCORE, INC. is the larger business by last-quarter revenue ($93.5M vs $85.1M, roughly 1.1× 4D Molecular Therapeutics, Inc.). 4D Molecular Therapeutics, Inc. runs the higher net margin — 22.8% vs 3.2%, a 19.6% gap on every dollar of revenue. On growth, 4D Molecular Therapeutics, Inc. posted the faster year-over-year revenue change (8508900.0% vs -1.5%). 4D Molecular Therapeutics, Inc. produced more free cash flow last quarter ($28.5M vs $2.9M). Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs 3.8%).
4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.
Comscore, Inc. is an American-based global media measurement and analytics company providing marketing data and analytics to enterprises, advertising agencies, brand marketers, and publishers.
FDMT vs SCOR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $85.1M | $93.5M |
| Net Profit | $19.4M | $3.0M |
| Gross Margin | — | 41.0% |
| Operating Margin | 17.3% | 7.0% |
| Net Margin | 22.8% | 3.2% |
| Revenue YoY | 8508900.0% | -1.5% |
| Net Profit YoY | 139.1% | -3.7% |
| EPS (diluted) | $0.43 | $9.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $85.1M | $93.5M | ||
| Q3 25 | $90.0K | $88.9M | ||
| Q2 25 | $15.0K | $89.4M | ||
| Q1 25 | $14.0K | $85.7M | ||
| Q4 24 | $1.0K | $94.9M | ||
| Q3 24 | $3.0K | $88.5M | ||
| Q2 24 | $5.0K | $85.8M | ||
| Q1 24 | $28.0K | $86.8M |
| Q4 25 | $19.4M | $3.0M | ||
| Q3 25 | $-56.9M | $453.0K | ||
| Q2 25 | $-54.7M | $-9.5M | ||
| Q1 25 | $-48.0M | $-4.0M | ||
| Q4 24 | — | $3.1M | ||
| Q3 24 | $-43.8M | $-60.6M | ||
| Q2 24 | $-35.0M | $-1.7M | ||
| Q1 24 | $-32.4M | $-1.1M |
| Q4 25 | — | 41.0% | ||
| Q3 25 | — | 40.6% | ||
| Q2 25 | — | 40.6% | ||
| Q1 25 | — | 39.6% | ||
| Q4 24 | — | 42.4% | ||
| Q3 24 | — | 41.2% | ||
| Q2 24 | — | 39.5% | ||
| Q1 24 | — | 42.3% |
| Q4 25 | 17.3% | 7.0% | ||
| Q3 25 | -67983.3% | 1.9% | ||
| Q2 25 | -396373.3% | -1.9% | ||
| Q1 25 | -383007.1% | -2.4% | ||
| Q4 24 | — | 4.1% | ||
| Q3 24 | -1704400.0% | -67.4% | ||
| Q2 24 | -849120.0% | -2.2% | ||
| Q1 24 | -136200.0% | -2.2% |
| Q4 25 | 22.8% | 3.2% | ||
| Q3 25 | -63195.6% | 0.5% | ||
| Q2 25 | -364386.7% | -10.6% | ||
| Q1 25 | -342657.1% | -4.7% | ||
| Q4 24 | — | 3.3% | ||
| Q3 24 | -1461433.3% | -68.5% | ||
| Q2 24 | -699060.0% | -2.0% | ||
| Q1 24 | -115717.9% | -1.2% |
| Q4 25 | $0.43 | $9.50 | ||
| Q3 25 | $-1.01 | $-0.86 | ||
| Q2 25 | $-0.98 | $-2.73 | ||
| Q1 25 | $-0.86 | $-1.66 | ||
| Q4 24 | — | $-0.47 | ||
| Q3 24 | $-0.79 | $-12.79 | ||
| Q2 24 | $-0.63 | $-1.19 | ||
| Q1 24 | $-0.66 | $-1.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $402.7M | $23.6M |
| Total DebtLower is stronger | — | $41.5M |
| Stockholders' EquityBook value | $505.7M | $111.4M |
| Total Assets | $566.7M | $407.7M |
| Debt / EquityLower = less leverage | — | 0.37× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $402.7M | $23.6M | ||
| Q3 25 | $305.1M | $26.7M | ||
| Q2 25 | $293.2M | $26.0M | ||
| Q1 25 | $321.4M | $31.0M | ||
| Q4 24 | $424.9M | $29.9M | ||
| Q3 24 | $501.9M | $20.0M | ||
| Q2 24 | $541.9M | $14.7M | ||
| Q1 24 | $525.9M | $18.7M |
| Q4 25 | — | $41.5M | ||
| Q3 25 | — | $41.4M | ||
| Q2 25 | — | $41.3M | ||
| Q1 25 | — | $41.3M | ||
| Q4 24 | — | $41.2M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $505.7M | $111.4M | ||
| Q3 25 | $369.0M | $-26.3M | ||
| Q2 25 | $420.9M | $-21.7M | ||
| Q1 25 | $469.7M | $-13.5M | ||
| Q4 24 | $510.6M | $-8.3M | ||
| Q3 24 | $552.9M | $-2.7M | ||
| Q2 24 | $588.3M | $45.8M | ||
| Q1 24 | $600.6M | $51.4M |
| Q4 25 | $566.7M | $407.7M | ||
| Q3 25 | $424.0M | $406.9M | ||
| Q2 25 | $473.6M | $415.9M | ||
| Q1 25 | $515.7M | $421.5M | ||
| Q4 24 | $560.4M | $430.2M | ||
| Q3 24 | $604.0M | $412.5M | ||
| Q2 24 | $620.1M | $474.1M | ||
| Q1 24 | $629.9M | $477.7M |
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.6M | $3.2M |
| Free Cash FlowOCF − Capex | $28.5M | $2.9M |
| FCF MarginFCF / Revenue | 33.5% | 3.1% |
| Capex IntensityCapex / Revenue | 0.1% | 0.3% |
| Cash ConversionOCF / Net Profit | 1.47× | 1.07× |
| TTM Free Cash FlowTrailing 4 quarters | $-109.9M | $21.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.6M | $3.2M | ||
| Q3 25 | $-46.5M | $9.5M | ||
| Q2 25 | $-43.4M | $932.0K | ||
| Q1 25 | $-47.8M | $9.1M | ||
| Q4 24 | $-134.6M | $-10.0M | ||
| Q3 24 | $-29.4M | $12.5M | ||
| Q2 24 | $-30.2M | $8.7M | ||
| Q1 24 | $-29.1M | $6.9M |
| Q4 25 | $28.5M | $2.9M | ||
| Q3 25 | $-46.6M | $9.4M | ||
| Q2 25 | $-43.4M | $787.0K | ||
| Q1 25 | $-48.4M | $8.7M | ||
| Q4 24 | $-138.4M | $-10.3M | ||
| Q3 24 | $-31.2M | $12.4M | ||
| Q2 24 | $-30.6M | $8.5M | ||
| Q1 24 | $-29.8M | $6.6M |
| Q4 25 | 33.5% | 3.1% | ||
| Q3 25 | -51765.6% | 10.5% | ||
| Q2 25 | -289620.0% | 0.9% | ||
| Q1 25 | -345635.7% | 10.1% | ||
| Q4 24 | -13837100.0% | -10.8% | ||
| Q3 24 | -1038966.7% | 14.0% | ||
| Q2 24 | -611840.0% | 10.0% | ||
| Q1 24 | -106421.4% | 7.6% |
| Q4 25 | 0.1% | 0.3% | ||
| Q3 25 | 101.1% | 0.1% | ||
| Q2 25 | 440.0% | 0.2% | ||
| Q1 25 | 4507.1% | 0.4% | ||
| Q4 24 | 378600.0% | 0.2% | ||
| Q3 24 | 59266.7% | 0.1% | ||
| Q2 24 | 6980.0% | 0.2% | ||
| Q1 24 | 2535.7% | 0.3% |
| Q4 25 | 1.47× | 1.07× | ||
| Q3 25 | — | 20.96× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -3.19× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FDMT
Segment breakdown not available.
SCOR
| Transferred Over Time | $77.1M | 83% |
| Research Insight Solutions | $14.6M | 16% |
| Related Party | $2.5M | 3% |
